Eltrombopag is well established in treatment of severe immune thrombocytopenia (ITP) and is increasingly commonplace in second-line management. A role is also suggested for both bridging therapy for surgery, as well as treating thrombocytopenia due to non-immune aetiologies. We present the largest single-centre experience with eltrombopag, with our cohort of 62 patients. Patients with severe ITP (n = 34) had 91Á2% response, which was sustained over a median of 18Á5 months. In 41Á4% of ITP cases (n = 14), complete response (CR-platelet count >100 9 10 9 /l) was achieved and in 2 cases, therapy was stopped and CR maintained. In our bridging group (n = 15) with a higher baseline platelet count, 93Á3% achieved a CR. In the non-ITP group (n = 13), a response was achieved in 76Á9%. In all groups, side effects were transient, with the drug discontinued in 2 patients due to minor complications (rash, nausea, diarrhoea). We conclude that eltrombopag is both effective and well tolerated as therapy in severe ITP. It is also advantageous in ITP patients who do not normally require therapy, but need a temporary platelet count boost pre-procedure. Furthermore, there are potentially far wider implications for the use of eltrombopag in counteracting thrombocytopenia beyond ITP, which merit further investigation.
Primary immune thrombocytopenia (ITP) is an acquired immune-mediated condition characterised by an isolated thrombocytopenia (platelet count <100 9 10 9 /l) in the absence of any underlying aetiology. Treatment is usually considered when the platelet count falls below a certain threshold (e.g. <30 9 10 9 /l) or with the presence of significant, typically mucosal, bleeding. First line treatment consists of steroids and/or intravenous immunoglobulin (IVIg), to boost platelet count, halt acute bleeding or raise the platelet count to a safe level to facilitate a procedure, or to allow other treatment to take effect. Second-line therapy is utilized to sustain a platelet count considered haemostatic for an individual patient who fails to respond to first line therapy or to allow its withdrawal (Provan et al, 2010) . There is far more heterogeneity of second line options, from those given once, aiming to provoke a sustained response (e.g. rituximab, splenectomy), to those requiring a more continuous administration, such as mycophenolate (MMF) (Taylor et al, 2015) or thrombopoietin (THPO) receptor agonists (Provan et al, 2010; Neunert et al, 2011) .
The recognition that ITP may be driven by reduced platelet production, in addition to increased platelet destruction, has been key to the development of the THPO receptor (MPL) agonists. Eltrombopag is a non-peptide small molecule, which activates THPO receptor-linked signal transduction pathways-mainly JAK/STAT and the p24/44 Mitogen-Activated Protein Kinase pathway (Merli et al, 2015) .
Eltrombopag was originally licensed for the treatment of chronic ITP and hepatitis C-associated thrombocytopenia. This has now expanded to severe aplastic anaemia, with its proposed action via stem cell activation (Desmond et al, 2014) . If the THPO receptor-linked pathway is activated with CD34 + haemopoietic precursor cells induced to differentiate into CD41 + megakaryocyte progenitor cells, this poses a potential therapeutic modality for other causes of thrombocytopenia. Data is emerging regarding the use of eltrombopag in other non-immune causes of thrombocytopenia-for example, potential in MYH9 mutation-related disorders (Pecci et al, 2010) . We present a case series of patients treated with eltrombopag to examine response rates, duration of effect and significant side effects. Our cohort includes patients with ITP, requiring treatment for refractory and/or severe disease, as well as 'pulsed' eltrombopag use in ITP, ordinarily not requiring treatment, but to cover surgery or other intervention.
To examine the potential of eltrombopag beyond ITP, our cohort includes thrombocytopenic cases related to both solid organ and haemopoietic malignancy.
Method
We retrospectively identified all patients who had received eltrombopag at a single institution, as part of standard treatment pathways, as well as those for whom special consideration was sought. All patients who started eltrombopag therapy from March 2012 (excluding trial patients) to January 2016 were included, with all cases re-examined in April 2016 to reassess response at follow-up. Cases were divided into 3 groups:
1. ITP patients with a 'severe' phenotype, defined according to the international consensus guidelines (Provan et al, 2010) , including patients with clinically relevant bleeding regardless of phase of disease -whether at presentation and sufficient to mandate treatment, or new bleeding symptoms requiring additional therapeutic intervention. Our cohort included those warranting second-line treatment beyond steroids and IVIg, and often having failed multiple previous treatments or with other comorbidities limiting treatment options. Bleeding manifestations were those typically seen in ITP, ranging from oral mucosal bleeding to rectal bleeding.
We collected baseline patient demographics, co-morbidities, sub-divided into primary and secondary ITP subtypes and examined previous treatment strategies.
2. Patients with ITP, who ordinarily would not require therapy, but for whom an increased platelet count was required to cover operative procedures/interventions were reviewed.
3. For non-ITP thrombocytopenic patients, indication for eltrombopag was examined on a case-by-case basis, according to benefit versus risk, given that the prescription was offlabel.
For the entire cohort, our key interest was whether a response to eltrombopag was evident in accordance with international guidelines for ITP management (Rodeghiero et al, 2009) . In short, a response to therapy in ITP was considered the ability to maintain a platelet count sufficient to prevent clinically significant bleeding. Further subdivision of definitions includes:
A 'Complete response (CR)': platelet count >100 9 10 9 /l. B 'Response (R)': platelet count >30 9 10 9 /l and at least 2-fold increase of the baseline count. C 'No response' defined as platelet count <30 9 10 9 /l or less than 2-fold increase from baseline, with symptoms of bleeding.
Beyond response per se, our data collection included duration of response, duration of follow-up, required dose of eltrombopag, necessity for intercurrent therapies, platelet transfusion requirement, side effects and complications.
Results
The total cohort of 62 patients included 36 males and 26 females, with follow-up from time of commencement of eltrombopag ranging from 1 month to 49 months. There were 2 patients who were initially entered into phase II and III trials (Cheng et al, 2011; Saleh et al, 2013) and hence were exposed from 2007 onwards with the remaining 60 patients prescribed eltrombopag from 2012 onwards.
The median age at time of initiating eltrombopag treatment was 55 years (range 18-98 years). The cohort was of mixed ethnicity, including white European (n = 51), Asian (n = 8), African (n = 2) and unknown (n = 1).
Initial dose of eltrombopag was given according to platelet count: 25 mg once daily (od) (n = 19), 50 mg od (n = 42) and 75 mg od (n = 1)).
The overall response was 90Á3%. In total, 6 patients failed to respond, 3 in the severe ITP group and 3 in the non-ITP group. Response rates across the three patient groups are summarized in Table I .
Group 1: severe ITP (n = 34)
Thirty-four patients were started on eltrombopag for treatment of severe ITP, including those patients with chronic refractory disease requiring treatment. There were 23 patients with primary ITP and 11 patients with secondary ITP. The latter group consisted of 5 patients with autoimmune aetiology and 6 patients with viral-induced ITP (associated with human immunodeficiency virus or hepatitis C virus [HCV] ). The median platelet count at commencement of eltrombopag therapy for severe ITP was 12 9 10 9 /l (range 0-43 9 10 9 /l).
However, in 24 cases this was associated with platelet supportive therapy before starting eltrombopag. Any reduction in the level of platelet support was associated with a documented significant decrease in platelet count, unacceptable because of previous intracranial haemorrhage or life-threatening thrombosis. Bleeding manifestations were those typically seen in ITP from oral mucosal bleeding, bruising, extensive petechiae, epistaxis (n = 6) and rectal bleeding (n = 3) and intracranial haemorrhage (n = 1). The median number of previous therapies used to treat this group was 4 (range 0-7 lines).
Previous therapy types included steroids (n = 30), IVIg (n = 27), rituximab (n = 19), MMF (n = 18), azathioprine (n = 8), splenectomy (n = 5), romiplostim (n = 3) and ciclosporin (n = 1).
The median time between diagnosis of ITP and the initiation of eltrombopag therapy was 25 months (ranging from commencement within a month of formal diagnosis to 20 years later, relating to availability of eltrombopag in patients with a long history of ITP). The group included patients who were non-responsive to a number of second line therapies (up to 7 documented in some cases), often still requiring rescue therapy for episodes of exacerbation of symptoms such as mucosal bleeding.
The use of eltrombopag increased year-upon-year from 2007 onwards, e.g. 4 cases in 2012 and 14 cases in 2015. This was associated with reduced use of other second line therapies earlier in the treatment pathway.
Initial effect of eltrombopag therapy showed CR in 14 (41Á2%), response in 17 (50%) and no response in 3 (8Á8%). In the severe ITP group, 8 patients required additional ondemand therapies, one or more, [steroid (n = 4), IVIg (n = 6) and MMF (n = 1)] to either secure or optimize a CR before a procedure or before eltrombopag had exerted its effect. Time to response was seen at a median of 4 weeks in this group (range 1-44 weeks).
At the most recent assessment, 28 patients remained on eltrombopag. These included 6 with a CR, 20 with a response and 2 with no platelet response. Of these latter 2 patients, 1 had clinical benefit with reduction of bleeding symptoms while the other had erratic compliance.
Doses were 25 mg alternate days (n = 6), 25 mg od (n = 8), 25 mg/50 mg alternate days (n = 2) 50 mg od (n = 9) and 75 mg od (n = 3). As the dose ranges suggest, many patients had their therapy weaned in order to maintain a haemostatic platelet count according to the dose required, and is reflected in the increased number of patients at follow-up with response but a decreased number with CR.
Of those patients who stopped eltrombopag (n = 6), 3 patients had achieved CR, and 3 had no response. In the patients with a CR at most recent follow-up, one was in relation to MMF and rituximab rather than eltrombopag. The other 2 patients maintained a CR despite being off therapy at most recent follow-up (7 months and 3 months post-drug cessation respectively).
Three patients had previous exposure to romiplostim: one stopped romiplostim at 3 lg/kg due to concern regarding THPO antibodies and the other two were treated in different institutions before coming to us. All three responded to eltrombopag, with a CR in one.
Group 2: ITP patients requiring short-term platelet support for chemotherapy, surgery or other procedure (N = 15)
This 'bridging' group of ITP patients was treated with eltrombopag specifically to raise their platelet count for an intervention, such as surgery, chemotherapy or other interventions, e.g. to support interferon therapy.
These 15 patients included 9 with primary ITP and 6 with secondary ITP. The latter group consisted of 1 patient with autoimmune aetiology, 1 patient with a new diagnosis of malignancy with known ITP and 4 patients with viralinduced ITP (associated with HCV).
Indications for bridging were interferon therapy for hepatitis C (n = 2), chemotherapy for breast cancer in a primary ITP patient (n = 1), activity/climbing holiday (n = 1) and pre-procedural (n = 11) -including neurosurgery, hernia repair and breast biopsy.
Up to 3 lines of previous therapies were used within this cohort, including steroids (n = 4), IVIg (n = 3), azathioprine (n = 1) and anti-D (n = 1). Initial doses of eltrombopag were 25 mg (n = 7) or 50 mg (n = 8), with responses and follow-up documented in Table I. In the bridging cohort, eltrombopag achieved a platelet count of >100 9 10 9 /l in 14 of the 15 patients, although it should be noted that the baseline platelet count was higher in this cohort (median 60 9 10 9 /l). There was a median time to response of 2 weeks (range 1-8 weeks), with up to 20 weeks for those with hepatitis C and therefore given a longer time to respond. In the one patient who did not reach a CR in terms of his platelet count, his clinical response was still considered valid. This patient had ITP secondary to hepatitis C with a baseline platelet count of 36 9 10 9 /l. Eltrombopag allowed the maintenance of his platelet count, thereby facilitating successful completion of his interferon treatment. Two patients required additional therapy to eltrombopag for planned intervention (IVIg and prednisolone respectively).
As planned for bridging therapy, the drug has subsequently been stopped in all patients. At the most recent assessment, 6 cases have maintained a CR and 9 are back at baseline platelet count -i.e. haemostatic off therapy but now with a platelet count <100 9 10 9 /l. For those patients who achieved CR, duration of this response off-therapy was a median of 5 months (range 2-21 months).
Group 3: non ITP associated thrombocytopenia (n = 13)
The non-ITP patient group was of diverse aetiology: colorectal carcinoma requiring chemotherapy likely to induce profound myelosuppression (n = 8), or thrombocytopenia directly related to the malignancy: myelodysplastic syndrome (MDS) (n = 1), Waldenstr€ om macroglobulinaemia transformed to high-grade lymphoma (n = 2) metastatic breast cancer (n = 1) and advanced uterine sarcoma (n = 1). One example includes this latter patient with advanced uterine sarcoma and an associated ITP. She was prescribed eltrombopag in an attempt to increase her platelet count to optimize anticoagulation for cancer-associated thrombosis and for chemotherapy to be given. She achieved a response with eltrombopag at 50 mg od, so it was continued until palliation and all therapies stopped.
Response to eltrombopag in this patient group is summarized in Table I .
At the most recent follow-up, 9 patients in this group had a platelet count of >100 9 10 9 /l but 7 have subsequently stopped chemotherapy, so resolution of a normal platelet count may be expected despite eltrombopag cessation. The remaining 2 patients who manifest a CR to the drug unfortunately died shortly after the most recent follow-up due to progression of malignancy. Four patients had no response in platelet count per se at follow-up. However, in the case with MDS, In an initial response was associated with no further need for platelet transfusion and reduced red cell transfusion requirement for 1 year.
Side effects. Overall, there were very few documented side effects thought to be clearly attributable to eltrombopag rather than other co-morbidities.
A total of 55 patients had no side effects. In the remaining 7 patients, side effects were as follows:
Drowsiness/fatigue (n = 2), skin rash/headache (n = 1), headache (n = 1), bilious vomiting (n = 1), mild headache/ plantar rash (but no improvement in these symptoms with cessation of drug over 2 months, n = 1) and disturbed sleep (n = 1).
Of note, one patient had a significant decrease in platelet count with an intercurrent viral infection, resolving with clinical recovery. No rescue medication was required and eltrombopag was continued throughout.
There were 8 deaths in our cohort, all from advanced malignancy, in Group 3. None were attributed to therapy for thrombocytopenia.
There were no thromboembolic events in the entire cohort related to eltrombopag. The drug was given to the previously described patient with advanced uterine sarcoma and extensive pulmonary emboli, in an attempt to alleviate her severe thrombocytopenia sufficiently to allow chemotherapy and anticoagulation. The thromboembolism was clearly antecedent to THPO agonist therapy in this case.
Discussion
Eltrombopag is primarily used at our centre to treat severe ITP, but also to bridge ITP patients temporarily, and now expanded to treat thrombocytopenia caused by other mechanisms. There was a response (platelet count >30 9 10 9 /l) in 90Á3% of the overall cohort, which was complete (platelet count >100 9 10 9 /l) in 54Á8% of the total group. Within the sub-groups; response was seen in 91Á2% of severe ITP, 100% of ITP requiring bridging and 76Á9% of the non-immune thrombocytopenic group. This response rate (91Á2%) in severe ITP was sustained over a median of 18Á5 months, albeit with a reduction in CR, attributable to a reduced dose of therapy. The dose was weaned to maintain haemostatic platelet counts and prevent bleeding symptoms, i.e. platelet counts between 50 and 100 9 10 9 /l. This high response rate to eltrombopag in ITP, whether to treat severe disease or for bridging, is in accordance with previous literature (Bussel et al, 2007 Cheng et al, 2011; Saleh et al, 2013) . Our own responses seem higher still compared to the original dose-finding studies, which used a primary end-point of platelet count >50 9 10 9 /l on day 43, reached in 70% of cases (Bussel et al, 2007) and 59% of cases ) respectively, at a dose of 50 mg/day. A likely explanation is our use of eltrombopag earlier in the second line treatment pathway. Many patients in our cohort are therefore severe rather than chronic refractory, with theoretically an increased likelihood of demonstrating a benefit. The role of THPO agonists in the ITP treatment pathway is not yet clear. The earlier use of eltrombopag in the treatment paradigm is important for several reasons: prevention of side effects associated with therapies often used before the availability of THPO agonists, avoiding inconvenience for patients with regard to day case admission for IVIg, avoiding unnecessary exposure to blood products and reduced immunosuppression. Beyond using eltrombopag in severe, chronic and/or refractory ITP, there is growing awareness of its role in temporarily boosting the platelet count prior to surgery or other intervention, such as dental procedures (Tarantino et al, 2014 (Tarantino et al, , 2015 Zaja et al, 2016) . Our bridging group had a higher baseline platelet count than that of the severe ITP group, but demonstrated a higher CR rate to that already published (Zaja et al, 2016) . Similarly, our 4 patients with viral-induced thrombocytopenia achieved platelet counts on eltrombopag that were comparable to the ENABLE (Eltrombopag to Initiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C-Related Liver Disease) data (Afdhal et al, 2014) , and endured beyond drug cessation.
Repeated or episodic use of eltrombopag has been described . Our cohort is relatively recent, and does not include patients exposed to repeat intermittent dosing in the same cyclical pattern -other than those for whom dose adaptations have been made according to platelet count. The ability to use eltrombopag repetitively has obvious economic implications for health care resources.
Since the THPO agents are still relatively new, it is not yet established whether one may be of use if the other has failed, or indeed if they can be used in conjunction in difficult cases. Our own cohort only included 3 patients who had previously tried and failed romiplostim: two of who have a continued response with eltrombopag and one with a particularly refractory phenotype and no response. A recent retrospective study suggests there is no cross-resistance with eltrombopag after sequential use following romiplostim (Gonzalez-Porras et al, 2015) , which implies flexibility in THPO agonist choice.
The initial response to eltrombopag in the patients requiring platelet count support for chemotherapy was important, allowing treatment to proceed based on oncology protocols requiring platelet counts >100 9 10 9 /l. Our cohort is limited, consisting mainly of solid organ malignancy requiring chemotherapy. However, alleviating thrombocytopenia associated with myelosuppressive cancer treatment allowed doses of both chemo-and radiotherapy to be maximized. Future potential for THPO agents may be to support even the most myelosuppressive regimens, such as in bone marrow transplantation (Liesveld et al, 2013) . The safety and efficacy of eltrombopag have been demonstrated in a number of randomized trials (Cheng et al, 2011; Saleh et al, 2013) . Although we documented temporary side effects in 7 patients (11%), these were mild and transient only and eltrombopag was stopped in only two patients whom could not tolerate therapy.
Adverse events occurring in the clinical trials, such as hepatic dysfunction, thromboembolism, bone marrow fibrosis and cataracts (Cheng et al, 2011; Bussel et al, 2013; Saleh et al, 2013; Ghanima et al, 2014) , were not witnessed in our cohort. Although eltrombopag is now licensed for severe aplastic anaemia, there remains theoretical concern regarding clonal evolution via stem cell pathway activation and secondary haematological malignancy. We did not observe such a phenomenon in our cohort, but our relatively smooth experience thus far may relate to patient numbers, duration of follow-up and lower doses of eltrombopag used. Our group is too small and uncontrolled to extrapolate any potential temporal relationship with cancer progression. In the 2 patients with haematological malignancy (MDS, highgrade lymphoma), eltrombopag allowed for a decreased transfusion requirement (drug commenced 20 months and 2 months before death respectively). In the first patient, death was caused by progressive MDS exacerbated by portal hypertension, cirrhosis and cardiac failure. Eltrombopag was deemed helpful in alleviating his cytopenia and transfusional demand. In the second patient, there was clear disease progression post-bone marrow transplantation and eltrombopag was instituted in the last 2 months of life in an attempt to offload transfusion need.
It is not clear which patients will sustain a response to eltrombopag despite cessation of drug, but in 2 of our severe ITP cohort patients, a CR was maintained at the most recent appraisal despite lack of response with previous treatment modalities and at least 3 months after stopping the drug. The therapeutic and financial implications of a sustained effect to drug are noteworthy.
In conclusion, our cohort demonstrates the potential for eltrombopag in severe and/or refractory ITP as a worthwhile treatment option -in accordance with the large comprehensive studies that led to its licence (Bussel et al, 2007 Cheng et al, 2011; Saleh et al, 2013) . Eltrombopag can be considered in patients refractory to a myriad of previous treatments, including romiplostim. Now established in clinical practice, eltrombopag's wider-reaching use is becoming more apparent. In ITP, the use of eltrombopag is preferential as an early second line therapy and there is a role for 'pulses' in supporting counts in an elective fashion. This may be increasingly prevalent in pre-operative planning of elective surgery, with clear connotations for healthcare resources. Of keen interest for the future will be the impact of eltrombopag in improving platelet count in malignancy, whether it be thrombocytopenia from the disease itself, or the treatment needed to combat or control cancer, haematological or otherwise. 
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